Non-vascular drug eluting stents as localized controlled drug delivery platform: Preclinical and clinical experience

Shaikh, Mohsin; Kichenadasse, Ganessan; Choudhury, Namita Roy; Butler, Ross N.; Garg, Sanjay

doi:10.1016/j.jconrel.2013.08.010

Cited by 39 publications

(19 citation statements)

References 78 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To prevent excessive tissue hyperplasia and the resulting reobstruction of the stented lumen, localized drug delivery via the stent has been attempted, and many antiproliferative drugs, including sirolimus and paclitaxel, are proven effective for lowering the restenosis rate of the procedure. In addition to antiproliferative drugs, some small interfering RNAs (siR-NAs) have been effectively employed to suppress tissue hyperplasia after stenting [12][13][14][15]. siRNAs can be incorporated into a stent-covering for localized siRNA delivery to the tissue around the stent.…”

Section: Introductionmentioning

confidence: 99%

Preparation of a Microporous Polyurethane Film with Negative Surface Charge for siRNA Delivery via Stent

Cho

Park

2017

International Journal of Polymer Science

View full text Add to dashboard Cite

Polyurethane (PU) and polyethylene glycol (PEG) were used to prepare a porous stent-covering material for the controlled delivery of small interfering RNA (siRNA). Microporous polymer films were prepared using a blend of polyurethane and water-soluble polyethylene glycol by the solution casting method; the PEG component was extracted in water to make the film microporous. This film was dipped in 2% poly(methyl methacrylate-co-methacrylic acid) solution to coat the polymer film with the anionic polyelectrolyte. The chemical components of the film surface were characterized by Fourier Transform Infrared (FTIR) spectroscopy and its structural morphology was examined by scanning electron microscopy (SEM). The effect of the negatively charged surface after attachment of a fluorescein isothiocyanate- (FITC-) labeled siRNA-polyethyleneimine complex onto the microporous polyurethane film and the controlled release of the complex from the film was investigated by fluorescence microscopy. Fluorescence microscopy showed the PU surface with intense fluorescence by the aggregates of the FITC-labeled-siRNA-PEI complex (measuring up to few microns in size); additionally, the negatively charged PU surface revealed broad and diffuse fluorescence. These results suggest that the construction of negatively charged microporous polyurethane films is feasible and could be applied for enhancing the efficiency of siRNA delivery via a stent-covering polyurethane film.

show abstract

Section: Introductionmentioning

confidence: 99%

Preparation of a Microporous Polyurethane Film with Negative Surface Charge for siRNA Delivery via Stent

Cho

Park

2017

International Journal of Polymer Science

View full text Add to dashboard Cite

show abstract

“…Medical devices nowadays like stents (vascular and non-vascular) are being developed not only for palliative purpose of treatment but also to aid for curative purposes, the development of drug eluting stents (DES) is a major leap forward on the said medical device (Groothuis et al, 2006;Jang et al, 2012;Shaikh et al, 2013;Song et al, 2011;Vilar et al, 2012). One major advantage on using stents is that it is being deployed on the site of obstruction where the cancer tumor is located (Shaikh et al, 2013). On the other hand such devices had their own limitations, number one is restenosis, second is migration and lastly the uncontrolled release of its drug payload.…”

Section: Introductionmentioning

confidence: 99%

Electrospun polyurethane/Eudragit ® L100-55 composite mats for the pH dependent release of paclitaxel on duodenal stent cover application

Aguilar

Unnithan

Amarjargal

et al. 2015

International Journal of Pharmaceutics

View full text Add to dashboard Cite

“…Drug-eluting non-vascular stents have remained elusive for various organs even after tremendous development in the vascular stents (13). This article deals with the development of the formulation and its evaluation for the advance stage esophageal cancer as a palliation option.…”

Section: Modified Formulation and The In Vivo Activitymentioning

confidence: 99%

In Vitro and In Vivo Assessment of Docetaxel Formulation Developed for Esophageal Stents

et al. 2016

Self Cite

View full text Add to dashboard Cite

Abstract. Esophageal cancer (EC) mostly affects the elderly population and is frequently diagnosed at an advanced stage. Self-expanding metal stents (SEMS) are the most popular mode of palliation, but they are associated with reocclusion caused by tumor growth. To overcome this problem, docetaxel (DTX)-loaded polyurethane formulations were prepared for stent application. The films were evaluated against the cancer cell lines, OE-19 and OE-21, and normal esophageal cell line Het-1A. The DTX and the formulations were evaluated in vitro for the cytotoxicity and in vivo in nude mice. It was found that DTX and the formulations have a weak activity against the EC cell lines and an even weaker activity against Het-1A cell line. Preliminary in vivo studies showed skin toxicity in nude mice necessitating modification of the formulation. Reevaluation in a mouse xenograft model resulted in toxicity at high dose formulations while the low dose formulation exhibited modest advantage over commercial IV formulation; however, there was no significant difference between the commercial IV and blank formulation. DTX combination with an anti-cancer agent having complementary mode of action and non-overlapping toxicity could yield better outcome in future.

show abstract

Non-vascular drug eluting stents as localized controlled drug delivery platform: Preclinical and clinical experience

Cited by 39 publications

References 78 publications

Preparation of a Microporous Polyurethane Film with Negative Surface Charge for siRNA Delivery via Stent

Preparation of a Microporous Polyurethane Film with Negative Surface Charge for siRNA Delivery via Stent

Electrospun polyurethane/Eudragit ® L100-55 composite mats for the pH dependent release of paclitaxel on duodenal stent cover application

In Vitro and In Vivo Assessment of Docetaxel Formulation Developed for Esophageal Stents

Contact Info

Product

Resources

About